
Many women believe that if they have no pain, unusual bleeding, or noticeable symptoms, there is little reason to visit a gynecologist. Unfortunately, this assumption can be dangerous when it comes to certain diseases.
Cervical cancer is an important example.
In its early stages, cervical cancer often causes no symptoms. Yet abnormal cellular changes that may eventually develop into cancer can frequently be detected years before invasive cancer appears.
This creates an extraordinary opportunity for prevention.
The cervix is the lower portion of the uterus that connects to the vagina. Cervical cancer develops when cells in this area undergo abnormal changes and begin growing uncontrollably.
In many cases, these changes develop slowly. Precancerous abnormalities may exist for years before progressing to invasive cancer.
With appropriate screening and follow-up treatment, many cases can be prevented.
Understanding the Role of HPV
Nearly all cervical cancers are associated with persistent infection by certain high-risk types of human papillomavirus, commonly known as HPV.
HPV is extremely common and is primarily transmitted through sexual contact and close genital skin-to-skin contact.
Most sexually active people are exposed to HPV at some point in their lives.
Importantly, having HPV does not mean a person has cancer.
In most individuals, the immune system controls the infection, and the virus eventually becomes undetectable. However, when certain high-risk types persist, they can cause cellular changes that may progress to precancer or cancer.
A positive HPV test also does not necessarily indicate a recent infection or infidelity. HPV can remain undetected for years, making it difficult or impossible to determine when transmission occurred.
Why Cervical Cancer Is Different
Cervical cancer is unusual because healthcare professionals have two powerful prevention tools: vaccination against the major viral cause and screening tests that can detect precancerous changes.
The Pap test, sometimes called a Pap smear, examines cervical cells for abnormalities.
The HPV test looks for high-risk types of the virus that can cause those abnormalities.
These tests serve different but complementary purposes.
A Pap test identifies abnormal cells, while an HPV test identifies the viral infection responsible for most cervical precancers and cancers.
Regular screening makes it possible to identify problems before they become life-threatening.
Updated Screening Recommendations in the United States
Cervical cancer screening recommendations have evolved as researchers have learned more about HPV and the development of cervical cancer.
Updated guidance endorsed by the American College of Obstetricians and Gynecologists in 2026 recommends that average-risk women ages 21 through 29 receive a Pap test every three years.
For women ages 30 through 65, clinician-collected primary high-risk HPV testing every five years is the preferred method.
Combined HPV and Pap testing every five years remains an acceptable alternative. Pap testing alone every three years can also be used in certain circumstances.
The American Cancer Society uses a somewhat different starting age, recommending routine screening beginning at age 25.
Because professional guidelines are not completely identical, women should discuss the appropriate schedule with their healthcare provider, considering their age, medical history, previous results, and individual risk factors. ACOG
A Major Development: Self-Collected HPV Testing
One of the most significant recent advances is the availability of self-collected samples for HPV screening.
For years, some women have avoided screening because they feel uncomfortable with pelvic examinations, have experienced previous medical trauma, face cultural barriers, or have difficulty accessing a healthcare professional.
Self-collection may help address some of these obstacles.
With an approved collection device, a woman can obtain her own vaginal sample, which is then sent to a laboratory for HPV testing.
Certain FDA-approved systems now permit sample collection at home.
However, women should use properly authorized testing systems obtained through appropriate healthcare channels rather than assuming that any internet-purchased HPV test is reliable.
Under the American Cancer Society’s updated recommendations, a negative self-collected HPV test is generally followed by repeat screening in three years.
A positive result may require additional testing, including a clinician-collected cervical sample or other follow-up procedures.
Self-collection does not replace all gynecologic examinations, but it provides another way to make preventive care more accessible.
HPV Vaccination: Prevention Before Exposure
Vaccination is another essential tool in preventing HPV-related cancers.
The HPV vaccine protects against viral types responsible for most cervical cancers and several other HPV-associated cancers.
The Centers for Disease Control and Prevention recommends routine vaccination at ages 11 or 12, although vaccination may begin at age 9.
People who were not adequately vaccinated earlier are generally recommended to receive catch-up vaccination through age 26.
For adults ages 27 through 45, vaccination may be considered after discussing individual circumstances and potential benefits with a healthcare professional.
HPV vaccination is important for both girls and boys.
The vaccine prevents new infections but does not treat infections that already exist.
Women who have been vaccinated must still follow appropriate cervical cancer screening recommendations because vaccination does not protect against every cancer-causing HPV type.
Can Cervical Cancer Cause Symptoms?
Early cervical cancer may not produce any noticeable symptoms.
As the disease progresses, some women experience abnormal vaginal bleeding, bleeding after sexual intercourse, bleeding between menstrual periods, or bleeding after menopause.
Unusual vaginal discharge, pelvic pain, and pain during intercourse may also occur.
These symptoms do not automatically indicate cancer. Many other medical conditions can cause similar problems.
However, abnormal bleeding—particularly after menopause—should always receive medical attention.
Screening is designed primarily for people without symptoms. A woman experiencing unusual bleeding needs a medical evaluation rather than simply waiting for her next scheduled screening test.
An Abnormal Result Does Not Mean Cancer
Receiving an abnormal Pap test or positive HPV result can be frightening.
However, most abnormal screening results do not mean that a woman has cervical cancer.
Depending on the findings, her age, and previous screening history, a healthcare professional may recommend repeat testing, additional laboratory evaluation, or colposcopy.
Colposcopy allows a clinician to examine the cervix using a specialized magnifying instrument.
If an area appears suspicious, a small tissue sample may be collected for laboratory examination.
When significant precancerous changes are found, treatment can remove or destroy abnormal tissue before invasive cancer develops.
The most important point is that follow-up matters.
A screening test cannot provide its full preventive benefit if abnormal findings are ignored or recommended follow-up is never completed.
Some Women Need a Different Screening Schedule
Standard screening recommendations apply to women at average risk.
Women with a history of serious cervical precancer or cervical cancer, those living with HIV, people with significant immune suppression, and certain other higher-risk patients may need a different schedule.
Women who have undergone a hysterectomy should also know whether their cervix was removed.
If the cervix remains, screening may still be necessary.
If both the uterus and cervix were removed for a benign condition and there is no history of serious cervical precancer or cancer, routine cervical screening is generally unnecessary.
Medical history is therefore essential when determining the appropriate screening plan.
What Happens After Age 65?
Many women assume that screening automatically ends at age 65.
That is not always correct.
Discontinuing screening depends on having an adequate history of normal results and meeting the relevant guideline’s criteria.
Women who have not been screened regularly, have a history of significant abnormalities, or have certain high-risk conditions may need continued screening beyond age 65.
Age alone should not determine whether screening stops.
What About the Cost?
Cost and access remain important barriers to preventive healthcare.
Women without adequate insurance may qualify for free or reduced-cost screening through public health programs and participating clinics.
In the United States, the National Breast and Cervical Cancer Early Detection Program helps eligible women obtain screening and diagnostic services.
New federal preventive-services guidance also expands provisions addressing the coverage of additional tests needed to complete cervical cancer screening.
For most affected health insurance plans, the updated coverage requirements begin January 1, 2027.
Women should check their current insurance benefits and available local programs rather than delaying care because they assume screening will be unaffordable.
Final Thoughts
Cervical cancer offers one of the clearest examples of the power of preventive medicine.
Unlike many diseases that are difficult to identify before symptoms appear, cervical precancerous changes can often be detected and treated before invasive cancer develops.
HPV vaccination, regular screening, and appropriate follow-up of abnormal results work together to reduce the risk of cervical cancer.
The absence of symptoms does not guarantee that the cervix is healthy.
For women who have postponed screening for several years, a conversation with a healthcare professional may be the first step toward protecting their future health.
Prevention begins with awareness, but it succeeds through action.
